Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F44555601%3A13430%2F22%3A43897486" target="_blank" >RIV/44555601:13430/22:43897486 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00216208:11110/22:10448082

  • Výsledek na webu

    <a href="https://www.liebertpub.com/doi/full/10.1089/dia.2022.0152" target="_blank" >https://www.liebertpub.com/doi/full/10.1089/dia.2022.0152</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1089/dia.2022.0152" target="_blank" >10.1089/dia.2022.0152</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study

  • Popis výsledku v původním jazyce

    Background: The aim was to compare the efficacy of real-time continuous glucose monitoring (rtCGM) and intermittently scanned continuous glucose monitoring (isCGM) focusing on glycated hemoglobin (HbA1c) as the primary endpoint.Methods: The CORRIDA LIFE was a 12-month, real-world, nonrandomized study that is part of the CORRIDA clinical trials program. The study compared rtCGM (Dexcom G5 or G6) and isCGM (FreeStyle Libre 14-Day; Abbott) in adults with type 1 diabetes (T1D). Only patients on multiple daily insulin injections or continuous subcutaneous insulin infusion with no automatic functions were included in this study. Primary outcome was the difference in HbA1c between study groups at 12 months.Results: One hundred ninety-one adults with T1D (mean age 40 +/- 13 years, HbA1c 8.1% +/- 3.4% [65 +/- 14 mmol/mol]) participated in this study; 81 patients initiated rtCGM and 110 initiated isCGM. After 12-months, HbA1c was significantly lower with rtCGM versus isCGM (7.1% +/- 3.1% [54.1 +/- 10.1 mmol/mol] vs. 7.7% +/- 3.3% [61.2 +/- 12.2 mmol/mol]), P = 0.0001. The percentage of time in hypoglycemia (&lt;70 mg/dL [&lt;3.9 mmol/L]) was lower among rtCGM vs. isCGM participants [4.3% +/- 2.8% vs. 6.4% +/- 5.3%], P = 0.003). Patients with rtCGM spent less time in clinically significant hypoglycemia (&lt;54 mg/dL [&lt;3.0 mmol/L]) (0.9% +/- 1.0% vs. 2.3% +/- 2.5%, P &lt; 0.0001) and more time in target range (70-180 mg/dL [3.9-10 mmol/L]) than isCGM users (67.5% +/- 14.8% vs. 57.8% +/- 17.0%), P = 0.0002.Conclusions: rtCGM was superior to isCGM in HbA1c, hypoglycemia, and other glycemic outcomes. Our findings provide guidance to clinicians when discussing monitoring options with their patients. The study was registered at www.clinicaltrials.gov (NCT04759495).

  • Název v anglickém jazyce

    Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study

  • Popis výsledku anglicky

    Background: The aim was to compare the efficacy of real-time continuous glucose monitoring (rtCGM) and intermittently scanned continuous glucose monitoring (isCGM) focusing on glycated hemoglobin (HbA1c) as the primary endpoint.Methods: The CORRIDA LIFE was a 12-month, real-world, nonrandomized study that is part of the CORRIDA clinical trials program. The study compared rtCGM (Dexcom G5 or G6) and isCGM (FreeStyle Libre 14-Day; Abbott) in adults with type 1 diabetes (T1D). Only patients on multiple daily insulin injections or continuous subcutaneous insulin infusion with no automatic functions were included in this study. Primary outcome was the difference in HbA1c between study groups at 12 months.Results: One hundred ninety-one adults with T1D (mean age 40 +/- 13 years, HbA1c 8.1% +/- 3.4% [65 +/- 14 mmol/mol]) participated in this study; 81 patients initiated rtCGM and 110 initiated isCGM. After 12-months, HbA1c was significantly lower with rtCGM versus isCGM (7.1% +/- 3.1% [54.1 +/- 10.1 mmol/mol] vs. 7.7% +/- 3.3% [61.2 +/- 12.2 mmol/mol]), P = 0.0001. The percentage of time in hypoglycemia (&lt;70 mg/dL [&lt;3.9 mmol/L]) was lower among rtCGM vs. isCGM participants [4.3% +/- 2.8% vs. 6.4% +/- 5.3%], P = 0.003). Patients with rtCGM spent less time in clinically significant hypoglycemia (&lt;54 mg/dL [&lt;3.0 mmol/L]) (0.9% +/- 1.0% vs. 2.3% +/- 2.5%, P &lt; 0.0001) and more time in target range (70-180 mg/dL [3.9-10 mmol/L]) than isCGM users (67.5% +/- 14.8% vs. 57.8% +/- 17.0%), P = 0.0002.Conclusions: rtCGM was superior to isCGM in HbA1c, hypoglycemia, and other glycemic outcomes. Our findings provide guidance to clinicians when discussing monitoring options with their patients. The study was registered at www.clinicaltrials.gov (NCT04759495).

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30304 - Public and environmental health

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2022

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    DIABETES TECHNOLOGY &amp; THERAPEUTICS

  • ISSN

    1520-9156

  • e-ISSN

    1557-8593

  • Svazek periodika

    24

  • Číslo periodika v rámci svazku

    12

  • Stát vydavatele periodika

    US - Spojené státy americké

  • Počet stran výsledku

    9

  • Strana od-do

    859-867

  • Kód UT WoS článku

    000892073400001

  • EID výsledku v databázi Scopus